Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

311
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
311
ATP Yield01:31

ATP Yield

79.1K
Cellular respiration produces 30 - 32 ATP per glucose molecule. Although most of the ATP results from oxidative phosphorylation and the electron transport chain (ETC), 4 ATP are gained beforehand (2 from glycolysis and 2 from the citric acid cycle).
The ETC is embedded in the inner mitochondrial membrane and is comprised of four main protein complexes and an ATP synthase. NADH and FADH2 pass electrons to these complexes, which pump protons into the intermembrane space. This distribution of...
79.1K
Nonlinear Pharmacokinetics: Role of Transporters01:27

Nonlinear Pharmacokinetics: Role of Transporters

298
A drug's nonlinear kinetics can be influenced by a diverse range of transporter proteins that serve as crucial players in drug distribution. These transporters, found within cells, can enhance or reduce local drug concentrations by facilitating the influx or efflux of drugs. For instance, the expression of xenobiotic transporters can be influenced by factors such as age and gender, potentially impacting the linearity of drug response.
Polymorphisms occurring in drug transporters can alter...
298
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

281
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Hepatic Drug Clearance: Effect of Protein Binding01:09

Hepatic Drug Clearance: Effect of Protein Binding

565
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
565
Primary Active Transport01:47

Primary Active Transport

199.9K
In contrast to passive transport, active transport involves a substance being moved through membranes in a direction against its concentration or electrochemical gradient. There are two types of active transport: primary active transport and secondary active transport. Primary active transport utilizes chemical energy from ATP to drive protein pumps that are embedded in the cell membrane. With energy from ATP, the pumps transport ions against their electrochemical gradients—a direction...
199.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

The Association of Alpha-1 Antitrypsin Deficiency and Arterial Aneurysms: An Update and Review.

Journal of clinical and translational hepatology·2026
Same authorSame journal

Dubin-Johnson and Rotor Syndromes: A Review and Update of Pathophysiological Mechanisms.

Journal of clinical and translational hepatology·2026
Same author

Congenital Portosystemic Shunts: A Review.

Journal of clinical and translational hepatology·2026
Same author

Analysis of Protein Binding to Liver Mitochondria by Horizontal Polyacrylamide Gel Electrophoresis Using a Converted Agarose Electrophoresis Unit.

Journal of clinical and translational hepatology·2026
Same author

Dengue Viral Infection and Associated Liver Disease.

Journal of clinical and translational hepatology·2026
Same author

Intrahepatic Cholestasis of Pregnancy: A Hot Topic Commentary.

Journal of clinical and translational hepatology·2025

Related Experiment Video

Updated: Feb 10, 2026

Mapping the Binding Site of an Aptamer on ATP Using MicroScale Thermophoresis
08:09

Mapping the Binding Site of an Aptamer on ATP Using MicroScale Thermophoresis

Published on: January 7, 2017

11.2K

ATP-binding Cassette Transporter Defects and Their Roles in Hepatic Diseases.

Danzhu Zhao1, George Y Wu2

  • 1Department of Medicine, University of Connecticut Health Center, Farmington, CT, USA.

Journal of Clinical and Translational Hepatology
|February 9, 2026
PubMed
Summary
This summary is machine-generated.

Mutations in ATP-binding cassette (ABC) transporters cause various liver diseases, from mild to severe. Genetic testing aids diagnosis and prognostication for these cholestatic hepatic diseases.

Keywords:
ATP-binding cassette transportersBile canaliculiCholestasisIntrahepaticNext generation sequencingZygosity

More Related Videos

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K
Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.9K

Related Experiment Videos

Last Updated: Feb 10, 2026

Mapping the Binding Site of an Aptamer on ATP Using MicroScale Thermophoresis
08:09

Mapping the Binding Site of an Aptamer on ATP Using MicroScale Thermophoresis

Published on: January 7, 2017

11.2K
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K
Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.9K

Area of Science:

  • Hepatology
  • Genetics
  • Molecular Biology

Background:

  • ATP-binding cassette (ABC) transporters are crucial for transporting molecules into bile canaliculi.
  • Defects in ABC transporters, such as BSEP, MDR3, ABCG5/8, and MRP2, lead to a spectrum of liver diseases.
  • Disease severity is modulated by genetic factors (zygosity, mutation type) and environmental influences.

Purpose of the Study:

  • To review hepatic diseases linked to ABC transporter mutations.
  • To discuss genetic and environmental factors influencing disease severity.
  • To cover clinical presentations, diagnostics, and therapeutic strategies for these cholestatic conditions.

Main Methods:

  • Literature review of hepatic diseases associated with ABC transporter mutations.
  • Analysis of genetic and environmental factors impacting disease severity.
  • Discussion of diagnostic approaches and treatment options.

Main Results:

  • Specific ABC transporter gene mutations (ABCB11, ABCB4, ABCG5/8, ABCC2) are associated with diverse liver pathologies.
  • Homozygous/compound heterozygous mutations typically cause severe, early-onset disease, while heterozygous mutations lead to milder forms.
  • Next-generation genetic testing offers high diagnostic and prognostic value.

Conclusions:

  • Understanding specific ABC transporter mutations is key for accurate diagnosis and prognostication.
  • Genetic and environmental factors significantly influence the clinical spectrum of these liver diseases.
  • Targeted therapies hold promise for managing severe cholestatic liver conditions caused by ABC transporter defects.